Fariborz Rousta; Ali Sharifi
Abstract
Introduction: The use of intrathecal morphine has the potential to reduce opioid consumption, improve pain relief, and minimize systemic opioid-related adverse effects. This study seeks ...
Read More
Introduction: The use of intrathecal morphine has the potential to reduce opioid consumption, improve pain relief, and minimize systemic opioid-related adverse effects. This study seeks to evaluate the impact of intrathecal morphine on opioid requirements and postoperative outcomes in patients undergoing pancreaticoduodenectomy.Materials and methods: Postoperative pain scores were recorded at regular intervals using a validated pain assessment tool such as the Numeric Rating Scale (NRS) or Visual Analog Scale (VAS). Opioid consumption was documented for the first 72 hours postoperatively, including the total dose of opioids administered, the number of rescue doses required, and the time to first rescue analgesia.Results: The group receiving intrathecal morphine exhibited a substantial decrease in opioid usage compared to the control group. The total opioid dose administered within the initial 72 hours postoperatively was notably lower in the intrathecal morphine group (4.29± 1.15 mg) in contrast to the control group (12.09 ± 2.25 mg) (p < 0.001).Conclusion: our study demonstrates that intrathecal morphine significantly reduces opioid consumption, improves pain control, and promotes faster recovery of gastrointestinal function in patients undergoing pancreaticoduodenectomy.